Abstract
A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year-1 interim analysis (P1-1.Virtual)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have